MedTrace Logo

A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.

NCT00903838 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2011-08-26

No results posted yet for this study

Summary

This is a multicenter, randomized, double blind, pramipexole-controlled parallel group study of pardoprunox as adjunctive treatment to levodopa.

Conditions

  • Advanced Stage Parkinson's Disease

Interventions

DRUG

pardoprunox

1.5 to 12 mg/day

DRUG

pramipexole

0.75-4.5 mg/day

Sponsors & Collaborators

  • Abbott Products

    lead INDUSTRY

Principal Investigators

  • Juliana Bronzova, MD · Abbott Healthcare Products B.V.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • Germany
  • Italy
  • Portugal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00903838 on ClinicalTrials.gov